Acute pancreatitis-progress and challenges a report on an international symposium

Pancreas

Volumn 44, Issue 8, 2015, Pages 1195-1210

  Afghani, Elham ^a   Pandol, Stephen J ^a   Shimosegawa, Tooru ^b   Sutton, Robert ^c   Wu, Bechien U ^d   Vege, Santhi Swaroop ^e   Gorelick, Fred ^f   Hirota, Morihisa ^b   Windsor, John ^g   Lo, Simon K ^a   Freeman, Martin L ^h   Lerch, Markus M ⁱ   Tsuji, Yoshihisa ^j   Melmed, Gil Y ^a   Wassef, Wahid ^k   Mayerle, Julia ⁱ  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^j KYOTO UNIVERSITY HOSPITAL   (Japan)

^k UNIVERSITY OF MASSACHUSETTS   (United States)

more..

Author keywords

Acute pancreatitis; CRAI; Post ERCP pancreatitis; Quality indicators; Treatment

Indexed keywords

INFUSION FLUID; BIOLOGICAL MARKER;

ACUTE PANCREATITIS; CLINICAL INDICATOR; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; INFORMATION DISSEMINATION; MEDICAL INFORMATION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPOSIUM; ACUTE DISEASE; DISEASE COURSE; JAPAN; MEDICAL SOCIETY; PANCREAS; PANCREATITIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ACUTE DISEASE; AMERICAN MEDICAL ASSOCIATION; BIOMARKERS; DISEASE PROGRESSION; HUMANS; JAPAN; PANCREAS; PANCREATITIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84944383385     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000500     Document Type: Conference Paper

References (153)

1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252-1261.
2. Hamada S, Masamune A, Kikuta K, et al. Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas. 2014;43:1244-1248.
3. Sand J, Välikoski A, Nordback I. Alcohol consumption in the country and hospitalizations for acute alcohol pancreatitis and liver cirrhosis during a 20-year period. Alcohol Alcohol. 2009;44:321-325.
4. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179-1187.e1-3.
5. Fagenholz PJ, Castillo CF, Harris NS, et al. Increasing united states hospital admissions for acute pancreatitis, 1988-2003. Ann Epidemiol. 2007;17:491-497.
6. Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas. 2006;33:323-330.
7. Spanier B, Bruno MJ, Dijkgraaf MG. Incidence and mortalityofacute and chronic pancreatitis in The Netherlands: a nationwide record-linked cohort study for the years 1995-2005. World J Gastroenterol. 2013;19: 3018-3026.
8. Yadav D, Ng B, Saul M, et al. Relationship of serum pancreatic enzyme testing trends with the diagnosis of acute pancreatitis. Pancreas. 2011;40: 383-389.
9. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102-111.
10. Dellinger EP, Forsmark CE, Layer P, et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. Ann Surg. 2012;256:875-880.
11. Deitch EA, Xu D, Kaise VL. Role ofthe gut in the development of injury-and shock induced SIRS and MODS: the gut-lymph hypothesis, a review. Front Biosci. 2006;11:520-528.
12. Mounzer R, Langmead CJ, Wu BU, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. Gastroenterology. 2012;142:1476-1482.
13. Yang CJ, Chen J, Phillips AR, et al. Predictors of severe and critical acute pancreatitis: a systematic review. Dig Liver Dis. 2014;46:446-451.
14. Hamada T, Yasunaga H, Nakai Y, et al. Japanese severity score for acute pancreatitis well predicts in-hospital mortality: a nationwide survey of 17, 901 cases. J Gastroenterol. 2013;48:1384-1391.
15. Yadav AK, Sharma R, Kandasamy D, et al. Perfusion CT: Can it predict the development of pancreatic necrosis in early stage of severe acute pancreatitis?. Abdom Imaging. 2015;40:488-499.
16. Tsuji Y, Takahashi N, Fletcher JG, et al. Subtraction color map of contrast-enhanced and unenhanced CT for the prediction of pancreatic necrosis in early stage of acute pancreatitis. AJR Am J Roentgenol. 2014; 202:W349-W356.
17. Wu BU, Banks PA. Clinical management of patients with acute pancreatitis. Gastroenterology. 2013;144:1272-1281.
18. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13:e1-e15.
19. Hamada T, Yasunaga H, Nakai Y, et al. Impact of hospital volume on outcomes in acute pancreatitis: a study using a nationwide administrative database. J Gastroenterol. 2014;49:148-155.
20. Hamada T, Yasunaga H, Nakai Y, et al. Continuous regional arterial infusion for acute pancreatitis: a propensity score analysis using a nationwide administrative database. Crit Care. 2013;17:R214.
21. Bakker OJ, Issa Y, van Santvoort HC, et al. Treatment options for acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2014;11:462-469.
22. Buxbaum J, Yan A, Yeh K, et al. Aggressive hydration with lactated ringer's solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography. Clin Gastroenterol Hepatol. 2014;12: 303-307.e1.
23. Warndorf MG, Kurtzman JT, Bartel MJ, et al. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011;9:705-709.
24. Wu BU, Hwang JQ, Gardner TH, et al. Lactated ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011;9:710-717.e1.
25. de-Madaria E, Soler-Sala G, Sánchez-Payá J, et al. Influence of fluid therapy on the prognosis of acute pancreatitis: a prospective cohort study. Am J Gastroenterol. 2011; 106: 1843-1850.
26. Horvath K, Freeny P, Escallon J, et al. Safety and efficacy of video-assisted retroperitoneal debridement for infected pancreatic collections: a multicenter, prospective, single-arm phase 2 study. Arch Surg. 2010;145:817-825.
27. van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010;362:1491-1502.
28. Gardner TB, Coelho-Prabhu N, Gordon SR, et al. Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: results from a multicenter U.S. series. Gastrointest Endosc. 2011;73:718-726.
29. Ross AS, Irani S, Gan SI, et al. Dual-modality drainage of infected and symptomatic walled-off pancreatic necrosis: long-term clinical outcomes. Gastrointest Endosc. 2014;79:929-935.
30. Freeman ML, Werner J, van Santvoort HC, et al. Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. Pancreas. 2012;41:1176-1194.
31. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59:845-864.
32. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001; 54:425-434.
33. Arain MA, Freeman ML. Pharmacologic prophylaxis alone is not adequate to prevent post-ERCP pancreatitis. Am J Gastroenterol. 2014; 109:910-912.
34. Freeman ML. Role of pancreatic stents in prevention of post-ERCP pancreatitis. JOP. 2004;5:322-327.
35. Coté GA, Kumar N, Ansstas M, et al. Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc. 2010;72:748-754.
36. Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol. 2009;104:31-40.
37. Mazaki T, Mado K, Masuda H, et al. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. J Gastroenterol. 2014;49:343-355.
38. Choksi NS, Fogel EL, Cote GA, et al. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. Gastrointest Endosc. 2015;81:150-155.
39. Freeman ML, Overby C, QiD. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc. 2004;59:8-14.
40. Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2007;7:6.
41. Bai Y, Gao J, Zou DW, et al. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas. 2008;37:241-246.
42. Rudin D, Kiss A, Wetz RV, et al. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol. 2007;22:977-983.
43. Bai Y, Gao J, Zhang W, et al. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther. 2008;28:557-564.
44. Zheng M, Bai J, Yuan B, et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol. 2008;8: 6-230X-8-6.
45. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414-1422.
46. Barkay O, Niv E, Santo E, et al. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc. 2008;22:1971-1976.
47. Sherman S, Cheng CL, Costamagna G, et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009;38:267-274.
48. Reed AM, Husain SZ, Thrower E, et al. Low extracellular pH induces damage in the pancreatic acinar cell by enhancing calcium signaling. J Biol Chem. 2011;286:1919-1926.
49. Bhoomagoud M, Jung T, Atladottir J, et al. Reducing extracellular pH sensitizes the acinar cell to secretagogue-induced pancreatitis responses in rats. Gastroenterology. 2009;137:1083-1092.
50. Hoque R, Farooq A, Ghani A, et al. Lactate reduces liver and pancreatic injury in toll-like receptor-and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity. Gastroenterology. 2014;146:1763-1774.
51. Brown A, Baillargeon JD, Hughes MD, et al. Can fluid resuscitation prevent pancreatic necrosis in severe acute pancreatitis? Pancreatology. 2002;2:104-107.
52. Gardner TB, Vege SS, Chari ST, et al. Faster rate of initial fluid resuscitation in severe acute pancreatitis diminishes in-hospital mortality. Pancreatology. 2009;9:770-776.
53. Mao EQ, Fei J, Peng YB, et al. Rapid hemodilution is associated with increased sepsis and mortality among patients with severe acute pancreatitis. Chin Med J (Engl). 2010;123:1639-1644.
54. Reddy N, Wilcox CM, Tamhane A, et al. Protocol-based medical management of post-ERCP pancreatitis. J Gastroenterol Hepatol. 2008; 23:385-392.
55. Sun ZX, Huang HR, Zhou H. Indwelling catheter and conservative measures in the treatment of abdominal compartment syndrome in fulminant acute pancreatitis. World J Gastroenterol. 2006;12:5068-5070.
56. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with trasylol: report of a controlled therapeutic trial. Br Med J. 1965;2: 627-629.
57. Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of trasylol therapy in primary acute pancreatitis. Br J Surg. 1978;65:337-341.
58. Trapnell JE, Rigby CC, Talbot CH, et al. Controlled study on trasylol in the treatment of acute pancreatitis. Med Welt. 1974;25:2106-2111.
59. Kakugawa Y, Takeda K, Sunamura M, et al. Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction. Nihon Shokakibyo Gakkai Zasshi. 1990;87:1444-1450.
60. Takeda K, Matsuno S, Sunamura M, et al. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996;171:394-398.
61. Piascik M, Rydzewska G, Milewski J, et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas. 2010;39:863-867.
62. Zhou M, Chen B, Sun H, et al. The efficiency of continuous regional intra-arterial infusion in the treatment of infected pancreatic necrosis. Pancreatology. 2013;13:212-215.
63. Yasuda T, Ueda T, Takeyama Y, et al. Treatment strategy against infection: clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitis. J Gastroenterol. 2007;42: 681-689.
64. Dawra R, Sah RP, Dudeja V, et al. Intra-acinar trypsinogen activation mediates early stages of pancreatic injury but not inflammation in mice with acute pancreatitis. Gastroenterology. 2011;141:2210-2217.e2.
65. Tsuji Y, Watanabe T, Kudo M, et al. Sensing of commensal organisms by the intracellular sensor NOD1 mediates experimental pancreatitis. Immunity. 2012;37:326-338.
66. Hoque R, Sohail M, Malik A, et al. TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Gastroenterology. 2011;141:358-369.
67. Tsuji Y, Yamamoto H, Yazumi S, et al. Perfusion computerized tomography can predict pancreatic necrosis in early stages of severe acute pancreatitis. Clin Gastroenterol Hepatol. 2007;5:1484-1492.
68. Wu BU, Johannes RS, Sun X, et al. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut. 2008;57: 1698-1703.
69. Singh VK, Wu BU, Bollen TL, et al. A prospective evaluation of the bedside index for severity in acute pancreatitis score in assessing mortality and intermediate markers of severity in acute pancreatitis. Am J Gastroenterol. 2009;104:966-971.
70. Papachristou GI, Muddana V, Yadav D, et al. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. Am J Gastroenterol. 2010;105:435-441 quiz 442.
71. Cho YS, Kim HK, Jang EC, et al. Usefulness of the bedside index for severity in acute pancreatitis in the early prediction of severity and mortality in acute pancreatitis. Pancreas. 2013;42:483-487.
72. Chen L, Lu G, Zhou Q, et al. Evaluation of the BISAP score in predicting severity and prognoses of acute pancreatitis in Chinese patients. Int Surg. 2013;98:6-12.
73. Kim BG, Noh MH, Ryu CH, et al. A comparison of the BISAP score and serum procalcitonin for predicting the severity of acute pancreatitis. Korean J Intern Med. 2013;28:322-329.
74. Khanna AK, Meher S, Prakash S, et al. Comparison of Ranson, Glasgow, MOSS, SIRS, BISAP, APACHE-II, CTSI scores, IL-6, CRP, and procalcitonin in predicting severity, organ failure, pancreatic necrosis, and mortality in acute pancreatitis. HPB Surg. 2013;2013:367581.
75. Park JY, Jeon TJ, Ha TH, et al. Bedside index for severity in acute pancreatitis: comparison with other scoring systems in predicting severity and organ failure. Hepatobiliary Pancreat Dis Int. 2013;12:645-650.
76. Senapati D, Debata PK, Jenasamant SS, et al. A prospective study of the bedside index for severity in acute pancreatitis (BISAP) score in acute pancreatitis: an Indian perspective. Pancreatology. 2014;14:335-339.
77. Zhang J, Shahbaz M, Fang R, et al. Comparison of the BISAP scores for predicting the severity of acute pancreatitis in Chinese patients according to the latest Atlanta classification. J Hepatobiliary Pancreat Sci. 2014;21:689-694.
78. Fleszler F, Friedenberg F, Krevsky B, et al. Abdominal computed tomography prolongs length of stay and is frequently unnecessary in the evaluation of acute pancreatitis. Am J Med Sci. 2003;325: 251-255.
79. Spanier BW, Nio Y, van der Hulst RW, et al. Practice and yield ofearly CT scan in acute pancreatitis: a Dutch observational multicenter study. Pancreatology. 2010;10:222-228.
80. Mortele KJ, Ip IK, Wu BU, et al. Acute pancreatitis: imaging utilization practices in an urban teaching hospital-analysis of trends with assessment of independent predictors in correlation with patient outcomes. Radiology. 2011;258:174-181.
81. Dachs RJ, Sullivan L, Shanmugathasan P. Does early ED CT scanning of afebrile patients with first episodes of acute pancreatitis ever change management? Emerg Radiol. 2015;22:239-243[ahead of print].
82. Bhattacharya A, Kochhar R, Sharma S, et al. PET/CT with 18F-FDG-labeled autologous leukocytes for the diagnosis of infected fluid collections in acute pancreatitis. J Nucl Med. 2014;55:1267-1272.
83. van Baal MC, Bollen TL, Bakker OJ, et al. The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis. Surgery. 2014;155:442-448.
84. Bakker OJ, van Santvoort H, Besselink MG, et al. Extrapancreatic necrosis without pancreatic parenchymal necrosis: a separate entity in necrotising pancreatitis? Gut. 2013;62:1475-1480.
85. Mayerle J, Hlouschek V, Lerch MM. Current management of acute pancreatitis. Nat Clin Pract Gastroenterol Hepatol. 2005;2:473-483.
86. Bakker OJ, van Brunschot S, van Santvoort HC, et al. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med. 2014;371:1983-1993.
87. Debas HT, Hancock RJ, Soon-Shiong P, et al. Glucagon therapy in acute pancreatitis: prospective randomized double-blind study. Can J Surg. 1980;23:578-580.
88. Durr HK, Maroske D, Zelder O, et al. Glucagon therapy in acute pancreatitis. Report of a double-blind trial. Gut. 1978;19:175-179.
89. Valderrama R, Pérez-Mateo M, Navarro S, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51:65-70.
90. Buchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. German pancreatitis study group. Gastroenterology. 1993;104:1165-1170.
91. Harada H, Miyake H, Ochi K, et al. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol. 1991;9:75-79.
92. Pezzilli R, Miglioli M. Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian acute pancreatitis study group. Dig Liver Dis. 2001;33:49-57.
93. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2:698-700.
94. Uhl W, Büchler MW, Malfertheiner P, et al. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45:97-104.
95. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48:62-69.
96. McKay CJ, Curran F, Sharples C, et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1997;84:1239-1243.
97. Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology. American College of Gastroenterology Guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400-1415; 1416.
98. Schneider L, Jabrailova B, Soliman H, et al. Pharmacological cholinergic stimulation as a therapeutic tool in experimental necrotizing pancreatitis. Pancreas. 2014;43:41-46.
99. Yildirim AO, Ince M, Eyi YE, et al. The effects of glycyrrhizin on experimental acute pancreatitis in rats. Eur Rev Med Pharmacol Sci. 2013; 17:2981-2987.
100. Gulcubuk A, Haktanir D, Cakiris A, et al. Effects of curcumin on proinflammatory cytokines and tissue injury in the early and late phases of experimental acute pancreatitis. Pa n c re at o l og y. 2013;13:347-354.
101. Lampropoulos P, Lambropoulou M, Papalois A, et al. The roleofapigenin in an experimental model of acute pancreatitis. J Surg Res. 2013;183: 129-137.
102. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J. 1948; 2:769-782.
103. Goodman LS, Wintrobe MM. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946;132:126-132.
104. Gray D. Thrombolysis: past, present, and future. Po s t gra d M e d J. 2006;82(968):372-375.
105. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40-51.
106. Marshall BC, Nelson EC. Accelerating implementation of biomedical research advances: critical elements of a successful 10 year cystic fibrosis foundation healthcare delivery improvement initiative. BMJ Qual Saf. 2014;23(suppl 1):i95-i103.
107. Gerasimenko JV, Gryshchenko O, Ferdek PE, et al. Ca2+ release-activated Ca2+ channel blockade as a potential tool in antipancreatitis therapy. Proc Natl Acad Sci USA. 2013;110:13186-13191.
108. Liu Y, Yuan J, Tan T, et al. Genetic inhibition of protein kinase Cε attenuates necrosis in experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014;307:G550-G563.
109. Yuan J, Liu Y, Tan T, et al. Protein kinase d regulates cell death pathways in experimental pancreatitis. Front Physiol. 2012;3:60.
110. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137: 1100-1111.
111. Lerch MM, Gorelick FS. Models of acute and chronic pancreatitis. Gastroenterology. 2013;144:1180-1193.
112. Abraham P, Rodriques J, Moulick N, et al. Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J Assoc Physicians India. 2013;61:535-538.
113. Le Campion ER, Jukemura J, Coelho AM, et al. Effects of intravenous administration of pentoxifylline in pancreatic ischaemia-reperfusion injury. HPB (Oxford). 2013;15:588-594.
114. Kruger B, Albrecht E, Lerch MM. The role of intracellular calcium signaling in premature protease activation and the onset of pancreatitis. Am J Pathol. 2000;157:43-50.
115. Kruger B, Lerch MM, Tessenow W. Direct detection of premature protease activation in living pancreatic acinar cells. Lab Invest. 1998;78:763-764.
116. Mooren FC, Turi S, Gunzel D, et al. Calcium-magnesium interactions in pancreatic acinar cells. FASEB J. 2001;15:659-672.
117. Fluhr G, Mayerle J, Weber E, et al. Pre-study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. BMC Gastroenterol. 2013;13:11-230X-13-11.
118. Muili KA, Jin S, Orabi AI, et al. Pancreatic acinar cell nuclear factor κB activation because of bile acid exposure is dependent on calcineurin. J Biol Chem. 2013;288:21065-21073.
119. Voronina S, Collier D, Chvanov M, et al. The role of Ca2+ influx in endocytic vacuole formation in pancreatic acinar cells. Biochem J. 2015;465:405-412.
120. Shalbueva N, Mareninova OA, Gerloff A, et al. Effects of oxidative alcohol metabolism on the mitochondrial permeability transition pore and necrosis in a mouse model of alcoholic pancreatitis. Gastroenterology. 2013;144:437-446.e6.
121. Lugea A, Tischler D, Nguyen J, et al. Adaptive unfolded protein response attenuates alcohol-induced pancreatic damage. Gastroenterology. 2011;140:987-997.
122. Pandol SJ, Gorelick FS, Lugea A. Environmental and genetic stressors and the unfolded protein response in exocrine pancreatic function-a hypothesis. Fro nt Phy si ol. 2011;2:8.
123. Nakamura Y, Do JH, Yuan J, et al. Inflammatory cells regulate p53 and caspases in acute pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2010;298:G92-G100.
124. Gukovskaya AS, Vaquero E, Zaninovic V, et al. Neutrophils and NADPH oxidase mediate intrapancreatic trypsin activation in murine experimental acute pancreatitis. Gastroenterology. 2002;122:974-984.
125. Zaninovic V, Gukovskaya AS, Gukovsky I, et al. Cerulein upregulates ICAM-1 in pancreatic acinar cells, which mediates neutrophil adhesion to these cells. Am J Physiol Gastrointest Liver Physiol. 2000;279:G666-G676.
126. Song M, Zaninovic V, Kim D, et al. Amelioration of rat cerulein pancreatitis by guamerin-derived peptide, a novel elastase inhibitor. Pancreas. 1999;18:231-239.
127. Sandoval D, Gukovskaya A, Reavey P, et al. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology. 1996;111:1081-1091.
128. Mayerle J, Schnekenburger J, Krüger B, et al. Extracellular cleavage of E-cadherin by leukocyte elastase during acute experimental pancreatitis in rats. Gastroenterology. 2005;129:1251-1267.
129. Ni HB, Ke L, Sun JK, et al. Beneficial effect of hypertonic saline resuscitation in a porcine model of severe acute pancreatitis. Pancreas. 2012;41:310-316.
130. Vigna SR, Shahid RA, Liddle RA. Ethanol contributes to neurogenic pancreatitis by activation of TRPV1. FASEB J. 2014;28:891-896.
131. James B. Trust the clinicians. Processes that caused adverse events a more urgent problem than human error. Mod Healthc. 2011;41:20.
132. Lohr KN. Medicare: A strategy for quality assurance. Washington, DC: National Academy Press; 1990.
133. Donabedian A. The role of outcomes inquality assessment and assurance. QRB Qual Rev Bull. 1992;18:356-360.
134. Brook RH, McGlynn EA, Cleary PD. Quality of health care. part 2: measuring quality of care. N Engl J Med. 1996;335:966-970.
135. Crandall W, Kappelman MD, Colletti RB, et al. ImproveCareNow: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis. 2011;17:450-457.
136. Crandall WV, Margolis PA, Kappelman MD, et al. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics. 2012;129:e1030-e1041.
137. Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCAL Appropriateness Method User's Manual. RAND: Santa Monica, CA; 2001.
138. Working Party of the British Society of Gastroenterology, Association of Surgeons of Great Britain and Ireland, Pancreatic Society of Great Britain and Ireland, Association of Upper GI Surgeons of Great Britain and Ireland. UK guidelines for the management of acute pancreatitis. Gut. 2005;54 suppl 3:iii1-iii9.
139. Mayumi T, Takada T, Kawarada Y, et al. Management strategy for acute pancreatitis in the JPN guidelines. J Hepatobiliary Pancreat Surg. 2006;13:61-67.
140. Forsmark CE, Baillie J. AGA Institute Clinical Practice and Economics Committee, et al. AGA institute technical review on acute pancreatitis. Gastroenterology. 2007;132:2022-2044.
141. Meier R, Beglinger C, Layer P, et al. ESPEN guidelines on nutrition in acute pancreatitis. european society of parenteral and enteral nutrition. Clin Nutr. 2002;21:173-183.
142. Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc. 2005;62:1-8.
143. Yasuda I, Nakashima M, Iwai T, et al. Japanese multicenter experience of endoscopic necrosectomy for infected walled-off pancreatic necrosis: The JENIPaN study. Endoscopy. 2013;45:627-634.
144. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care. 2003;15:523-530.
145. Paran H, Mayo A, Paran D, et al. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci. 2000;45:2247-2251.
146. Wang R, Yang F, Wu H, et al. High-dose versus low-dose octreotide in the treatment of acute pancreatitis: a randomized controlled trial. Peptides. 2013;40:57-64.
147. Yang F, Wu H, Li Y, et al. Prevention of severe acute pancreatitis with octreotide in obese patients: a prospective multi-center randomized controlled trial. Pancreas. 2012;41:1206-1212.
148. Siriwardena AK, Mason JM, Balachandra S, et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut. 2007;56:1439-1444.
149. Bansal D, Bhalla A, Bhasin DK, et al. Safety and efficacy of vitamin-based antioxidant therapy in patients with severe acute pancreatitis: a randomized controlled trial. Saudi J Gastroenterol. 2011;17:174-179.
150. Pettilä V, Kyhälä L, Kylänpää ML, et al. APCAP-activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care. 2010;14:R139.
151. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995;82:1414-1420.
152. Bollen TL, Singh VK, Maurer R, et al. A comparative evaluation of radiologic and clinical scoring systems in the early prediction of severity in acute pancreatitis. Am J Gastroenterol. 2012;107:612-619.
153. Barnato AE, Garber AM. Performance of the RAND appropriateness criteria. Med Decis Making. 2003;23:177-179.